FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4237782545> ?p ?o ?g. }

• W4237782545 endingPage "4185" @default.
• W4237782545 startingPage "4185" @default.
• W4237782545 abstract "4185 Background: Results from clinical trials using octreotide for treatment of advanced HCC are conflicting. Current objective was to evaluate prognostic factors before and during treatment with Sandostatin LAR 30 mg (monthly). Methods: Prospective cohort of 75 patients. They were treated for a minimum of six months or until one final endpoint (progression or death) was reached. Optimal cut-offs were derived from ROC analysis. Results: (logrank tests): Progression within or later than 90 days of treatment was the best clinical decision making for longterm survival outcome (p<0.0001), median PFS was 468 days. A CLIP score > 2 decreased median survival from 230 to 113 days (p<0.01), okuda stage 3 was similiar. 79% of patients had an increased uptake by octreoscan (>1.5 fold than non-tumorous liver). An uptake <2 fold was associated with longer survival (median: 391 vs. 158 days, p=0.05), in patients evaluable during follow up, octreoscan uptake was unchanged in most cases. A prestudy serum VEGF-A value of >660 pg/ml shortened survival from 205 to 95 days (p <0.01). A decrease in VEGF-A by month 3 or 6 of treatment below a ratio of 0.7 was predictive best: by 2.5 years 45% of patients vs. 8% of patients survived (p=0.01). Other serum markers evaluated with significant differences in survival were soluble interleukin 2 receptor and osteopontin. Their corresponding cut-offs of 1310 pg/ml and 1060 U/l discriminated between 220–230 and 114 days of survival (p<0.01 each). In contrast to previous reports, serum IGF-1 was marginally associated with survival outcome in this study. Conclusions: Overall median time to progression (122 days) and median survival (153 days) in our study was short. However, for the first time, we are able to identify a subgroup of patients with no measurable HCC tumor progression and long-term survival due to treatment with octreotide. The most intriguing finding was the association between VEGF-A decline and treatment response, thus suggesting the inhibition of angiogenesis as the main factor of action for octreotide. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Novartis Pharma, Nueremberg, Germany" @default.
• W4237782545 created "2022-05-12" @default.
• W4237782545 creator A5012335345 @default.
• W4237782545 creator A5028863833 @default.
• W4237782545 creator A5078223594 @default.
• W4237782545 creator A5016313007 @default.
• W4237782545 date "2004-07-15" @default.
• W4237782545 modified "2023-09-27" @default.
• W4237782545 title "Prognostic factors associated with treatment response to octreotide in advanced hepatocellular cancer (HCC)" @default.
• W4237782545 doi "https://doi.org/10.1200/jco.2004.22.14_suppl.4185" @default.
• W4237782545 hasPublicationYear "2004" @default.
• W4237782545 type Work @default.
• W4237782545 citedByCount "0" @default.
• W4237782545 crossrefType "journal-article" @default.
• W4237782545 hasAuthorship W4237782545A5012335345 @default.
• W4237782545 hasAuthorship W4237782545A5016313007 @default.
• W4237782545 hasAuthorship W4237782545A5028863833 @default.
• W4237782545 hasAuthorship W4237782545A5078223594 @default.
• W4237782545 hasConcept C126322002 @default.
• W4237782545 hasConcept C141071460 @default.
• W4237782545 hasConcept C146357865 @default.
• W4237782545 hasConcept C151730666 @default.
• W4237782545 hasConcept C188816634 @default.
• W4237782545 hasConcept C203092338 @default.
• W4237782545 hasConcept C2776297358 @default.
• W4237782545 hasConcept C2778019345 @default.
• W4237782545 hasConcept C2781025020 @default.
• W4237782545 hasConcept C535046627 @default.
• W4237782545 hasConcept C71924100 @default.
• W4237782545 hasConcept C72563966 @default.
• W4237782545 hasConcept C86803240 @default.
• W4237782545 hasConcept C90924648 @default.
• W4237782545 hasConceptScore W4237782545C126322002 @default.
• W4237782545 hasConceptScore W4237782545C141071460 @default.
• W4237782545 hasConceptScore W4237782545C146357865 @default.
• W4237782545 hasConceptScore W4237782545C151730666 @default.
• W4237782545 hasConceptScore W4237782545C188816634 @default.
• W4237782545 hasConceptScore W4237782545C203092338 @default.
• W4237782545 hasConceptScore W4237782545C2776297358 @default.
• W4237782545 hasConceptScore W4237782545C2778019345 @default.
• W4237782545 hasConceptScore W4237782545C2781025020 @default.
• W4237782545 hasConceptScore W4237782545C535046627 @default.
• W4237782545 hasConceptScore W4237782545C71924100 @default.
• W4237782545 hasConceptScore W4237782545C72563966 @default.
• W4237782545 hasConceptScore W4237782545C86803240 @default.
• W4237782545 hasConceptScore W4237782545C90924648 @default.
• W4237782545 hasIssue "14_suppl" @default.
• W4237782545 hasLocation W42377825451 @default.
• W4237782545 hasOpenAccess W4237782545 @default.
• W4237782545 hasPrimaryLocation W42377825451 @default.
• W4237782545 hasRelatedWork W2027863009 @default.
• W4237782545 hasRelatedWork W2047967234 @default.
• W4237782545 hasRelatedWork W2370316128 @default.
• W4237782545 hasRelatedWork W2766588635 @default.
• W4237782545 hasRelatedWork W4240236077 @default.
• W4237782545 hasRelatedWork W4251581028 @default.
• W4237782545 hasRelatedWork W4306253774 @default.
• W4237782545 hasRelatedWork W4317038016 @default.
• W4237782545 hasRelatedWork W2014450888 @default.
• W4237782545 hasRelatedWork W2324379075 @default.
• W4237782545 hasVolume "22" @default.
• W4237782545 isParatext "false" @default.
• W4237782545 isRetracted "false" @default.
• W4237782545 workType "article" @default.